Open AccessMyocardial metabolic background on chemotherapy and means of their correction
Author(s) -
Yu. A. Vasyuk,
Васюк Юрий Александрович,
Evgeny Shkolnik,
Школьник Евгений Леонидович,
V V Nesvetov,
Несветов Валерий Валерьевич,
L. D. Shkolnik,
Школьник Леонид Донович,
Г. В. Варлан,
Варлан Геннадий Валентинович,
A. V Pilschikov,
Пильщиков Андрей Валерьевич
Publication year - 2013
Publication title -
cardiosomatika
Language(s) - English
Resource type - Journals
eISSN - 2658-5707
pISSN - 2221-7185
DOI - 10.26442/cs45027
Subject(s) - cardiotoxicity , medicine , chemotherapy , doxorubicin , oncology , intensive care medicine
Recent years have seen significant progress in the treatment of many oncologicaldiseases associated with the development of new chemotherapeutic agents. Typically, they are used in combination with classical chemotherapy regimens that in-clude doxorubicin. In the background of this combined treatment significant prolongation of life of the patients was noted, but at the same time the risk of cardiotoxicity was considerably increased. The survey provides information about the cardiomyocytesmetabolic disorders during therapy with anthracyclines, discussing the possibility of pathogenetic treatment and prevention.